Dulce C. Macias-Ceja1
María D. Barrachina
Dolores Ortiz-Masià- 1Departamento de Farmacología and CIBER, Facultad de Medicina y Odontología, Universitat de Valencia, Valencia, Spain
- 2Departamento de Medicina, Facultad de Medicina y Odontología, Universitat de Valencia, Valencia, Spain
Chronic inflammation is often associated with fibrotic disorders in which an excessive deposition of extracellular matrix is a hallmark. Long-term fibrosis starts with tissue hypofunction and finally ends in organ failure. Intestinal fibrosis is not an exception, and it is a frequent complication of inflammatory bowel disease (IBD). Several studies have confirmed the link between deregulated autophagy and fibrosis and the presence of common prognostic markers; indeed, both up- and downregulation of autophagy are presumed to be implicated in the progression of fibrosis. A better knowledge of the role of autophagy in fibrosis may lead to it becoming a potential target of antifibrotic therapy. In this review we explore novel advances in the field that highlight the relevance of autophagy in fibrosis, and give special focus to fibrosis in IBD patients.
Introduction
Fibrotic diseases are characterized by endless inflammation, tissue wounds, and injuries. Fibrosis is common to various chronic inflammatory diseases in organs (lung, intestine, liver, kidney, or skin) and is responsible for a death rate of close to 50% in developed countries (W.-J. Zhang Wen-Juan et al., 2021). Fibrotic tissues show a decrease in parenchymal cells parallel to an increase in fibrous connective tissue. The fibrotic process is orchestrated by specialized pro-resolving lipid mediators, cytokines, chemokines and growth factors released by immune and non-immune cells. Alterations in metabolic pathways in activated fibroblasts are thought to be responsible for excessive extracellular matrix (ECM) production. The role of autophagy in the fibrotic process is dual and can be bidirectional. To study the profibrotic or antifibrotic role of autophagy, it is necessary to consider several parameters, such as the specific cell type analysed, the stimuli used, the experimental model and the stage of the fibrosis process, as well as to differentiate between the autophagy-mediated effects of secondary compensatory reactions produced by impaired autophagy. In this review we provide insight into recent advances in the field that suggest the implication of autophagy in fibrosis, with special focus given to the fibrosis observed in inflammatory bowel disease (IBD) patients.
IBD is divided into two types: Crohn’s disease (CD) and ulcerative colitis (UC). The incidence of these pathologies in the adult population seems to have stabilized in the western world, but is increasing in paediatric populations and in previously low-incidence areas in developing countries. Both UC and CD share some clinical and demographic characteristics, but differ in the tissue damage they produce and their prognosis. UC is characterized by inflammation and ulcerations that affect the mucosal and submucosal layers of the colon. In contrast, the lesions in CD are common in the distal ileum and right colon, but can affect any part of the gastrointestinal tract. CD is characterized by transmural inflammation (ileal CD accounts for about 80% of cases) and inflammation of the colon (about 20% of cases) (Ng et al., 2017). Intestinal fibrosis is a common and serious complication of IBDs, including CD and UC. Despite the introduction of new biologic therapies, the incidence of stricture formation and stenosis of the intestine in IBD patients has not been reduced significantly (D’Haens et al., 2022; S et al., 2022). As we will detail in the following sections, IBD pathology is mediated by several perturbations related with a defective autophagy, including a malfunctioning mucosal barrier, dysregulation of the immune response, altered microbiota composition and, eventually, the fibrotic process (Foerster et al., 2022), the main focus of this review.
Autophagy is an intracellular pathway that involves the degradation of cytosolic portions, protein aggregates, and organelles through their delivery into lysosomes (Noboru Mizushima et al., 2008). It is vital for the homeostatic turnover of aged proteins and organelles and cell differentiation. In addition, autophagy is activated under situations of low energy and cellular stress, and it is finely regulated by hormones, nutrients and environmental conditions. Therefore, it is not surprising that changes in autophagy modulate the pathogenesis of multiple diseases, including fibrotic diseases. The literature describes three different types of autophagy depending on how substrates are deposited in lysosomes for removal (macroautophagy, microautophagy, and chaperone-mediated autophagy). Macroautophagy (autophagy), the classic, most common type, involves nucleation, membrane modification, development of autophagic lysosomes, and destruction of the enclosed molecules. In mammals, autophagy is initiated by the Unc-51-like kinase-1 (ULK1) complex (Zachari y Ganley, 2017), which¸ together with the class III phosphatidylinositol 3-kinase (PtdIns3K) complex (Kishi-Itakura et al., 2014), contributes to the assembling of the autophagic machinery in the endoplasmic reticulum (ER). Complexes of autophagy-related gene (ATG) proteins, including ATG5, ATG12, and ATG16L1, are attached to the autophagosomes for “maturation” (N. Mizushima et al., 1998). Target molecules can be labelled by ubiquitin tags, as well as cargo receptors, such as CALCOCO2/NDP52 and SQSTM1/P62 (Noboru Mizushima, 2018). After lysosomal fusion has occurred, the contents are digested, and nutrients are recycled (Noboru Mizushima, 2018). The onset of autophagy is closely controlled by various members of the mTOR pathway, such as MTORC1, AMPK and TFEB/TFE3 (Ramirez Reyes, Cuesta, y Pause, 2021). That said, the control of autophagic flux can be regulated in many other ways. In the case of specialized forms of autophagy, including xenophagy and mitophagy, nucleotide binding oligomerization domain containing 1 (NOD1) and NOD2 can begin autophagy through direct interaction with ATG16L1 upon detection of bacterial infection. Then there is the case of miRNAs, which can regulate autophagy through different molecular pathways (NOD2, ATG16L1, ULK1 or ATG9) (Foerster et al., 2022; S. Wang Shiyuan et al., 2018)
Diverse review articles have analyzed the role of autophagy in various fibrotic tissues, such as the lung, liver or kidney, but none have focused on the specific field of IBD fibrosis and how it is related to autophagy process. Existing reviews on autophagy and IBD does so either from the pathophysiological point of view of the disease or are based on acute models of colitis or human samples from patients with non-fibrotic IBD. The analysis of the interaction between autophagy and intestinal fibrosis will help to develop new molecular targets of IBD fibrotic therapy. The present review aims to summarize the evidence of the role of autophagy in the initiation, development, and maintenance of intestinal fibrosis in IBD.
Material and methods
A comprehensive search of MEDLINE/PubMed, Cochrane Library, CINAHL, Scopus, and Embase was conducted in May 2023. In all cases the keywords “fibrosis and inflammatory bowel disease and autophagy” were employed. In Pubmed, 21 results were found, of which 12 were reviews and 9 were research articles. In Scopus, 33 documents were found: 18 reviews, 11 scientific articles, 2 book chapters, 1 editorial and 1 conference. In Cochrane Library we did not find any articles. In CINAHL, 4 documents were found: 1 review and 3 scientific articles. In Embase, we found 57 articles: 27 reviews, 13 scientific articles, 1 short survey, 1 editorial and 15 conference. Duplications were eliminated and the articles that addressed the objective of this work–i.e., to explore the role of autophagy in intestinal fibrosis in the context of inflammatory bowel disease—were selected and reviewed. Research with acute models of colitis were reviewed but not considered in Tables 2, 3
A brief outline of autophagy in the pathophysiology of IBD
IBD is a multifactorial disease involving factors such as dysbiosis, alteration of the mucosal barrier, genetic mutations and environmental factors. The relationship of autophagy with this disease is widely recognized, both in the early stages and during its development. In general, as shown in Figure 1, alterations in autophagy have been associated with dysfunction of the epithelial barrier, including defects in the secretion of antimicrobial peptides, alterations in the endoplasmic reticulum stress response, dysbiosis, and altered immune responses (Figure 1). Genome-wide association studies (GWASs) have identified IBD-relevant autophagy genes underlying susceptibility to IBD, and especially to CD, which tends to be more affected by genetic factors than UC. Mutation of genes in the autophagy pathway, including immunity-related GTPase M (IRGM) (Parkes et al., 2007; McCarroll et al., 2008), leucine rich repeat serine/threonine-protein kinase 2 (lrrk2) (Barrett et al., 2008; Gardet et al., 2010), Ulk1 (Henckaerts et al., 2011), Atg16l1 (Hampe et al., 2007), and Nod2 (Hugot et al., 2001; Ogura et al., 2001), predisposes individuals to severe CD. Cells obtained from CD patients with risk alleles for either Atg16l1 or Nod2 cannot initiate the antigen presentation, the autophagocytic process, or bacterial clearance (Hampe et al., 2007; Parkes et al., 2007). In CD patients, the polymorphisms of autophagy-related genes, Irgm, Ulk1 and X box-binding protein 1 spliced-1 (Xbp1) imply weaknesses in the initial immune response, principally innate immune pathways and the management of intracellular bacteria (Rioux et al., 2007). Other mutations or deletion of autophagy-related genes linked with CD pathogenesis include Atg5 in Paneth cells, Atg4 and transcription factor 4 (Tcf4) (S.-L. Wang Shu-Ling et al., 2018). In UC patients, the autophagy process is undermined through reduction of autophagy-related transcription factor 4 (Atf4) activity (Hu et al., 2019, 4), mTOR-dependent autophagy flux deficiency (M. Zhou et al., 2018), and a deficient VDR expression and alteration of vitamin D/VDR signalling (Bakke y Sun, 2018) that may modulate intestinal inflammation by promoting autophagy-mediated inflammasome inhibition (Bakke y Sun, 2018; Karimi et al., 2019; Law et al., 2019). IMP1/IGF2BP1, a RNA binding protein which is increased in CD and CU patients, has been implicated in autophagy inhibition. Following dextran sulphate sodium (DSS)-mediated injury, Imp1ΔIEC mice show enhanced colonic mucosal recovery, increased autophagy flux and upregulation of ATG5 (Chatterji et al., 2019). In IBD murine models, a protective role of autophagy has been demonstrated through the nuclear receptor binding factor 2 (NFRP2) and Metrnl. NFRP2 regulates autophagy and is necessary for the destruction of apoptotic cells and mitigation of inflammation (Wu et al., 2021). In epithelial cells, deficiency of Metrnl—a secreted protein highly expressed in the intestinal epithelium of UC patients—reduces the autophagy activated by DSS in intestinal epithelial cells and aggravates the disease in DSS-treated mice (S.-L. Zhang Meixia et al., 2020).Over-induction of autophagy can produce negative effects, precipitating autophagic cellular death, for instance. In the DSS model, it has been described that failure of Erbin–a protein implicated in the polarity of epithelial cells, and highly expressed in the intestinal mucosa—produces an over-induction of autophagy and autophagic cell death-triggered inflammation (Shen et al., 2018) (Figure 2).
FIGURE 1. Simplified illustration of the role of defective autophagy in the pathophysiology of Inflammatory Bowel Disease (IBD). The illustration shows the two main processes in which autophagy is involved in the pathogenesis of IBD: epithelial and immune dysfunction.
FIGURE 2. Pathways and genetic and epigenetic basis of autophagy involved in the pathophysiology of inflammatory bowel disease (IBD). In Crohn’s Disease (CD), the mutation or deletion of some autophagy-related genes (blue box) has been related with CD. IGF2BP1/IMP1 has been implicated in autophagy inhibition in CD and Ulcerative Colitis (UC). In UC patients, there is a reduction of the autophagy process through the reduction of ATF4 activity, mTOR-dependent autophagy flux deficiency and low VDR expression and defective vitamin D/VDR signalling. The illustration also features miRNAs described as modulators of autophagy in IBD patients. Finally, we can see the advances made with murine models of IBD that link autophagy to IBD pathology. IGF2BP1/IMP1, Insulin-like growth factor 2 RNA binding protein 1; IRGM, immunity-related GTPase M; LRRK2, leucine-rich repeat serine/threonine-protein kinase 2; ULK-1, Unc-51-like kinase-1; ATG16L1, autophagy-related protein 16-like protein 1; NOD2, nucleotide binding oligomerization domain containing protein 2; ATG5, autophagy-related gen 5; ATG4, autophagy-related gen 4; TCF4, transcription factor 4; XBP1, X box-binding protein 1 spliced-1; mTOR, mammalian target of rapamycin; ATF4, autophagy-related transcription factor 4; VDR, vitamin D receptor; NRBF2, nuclear receptor binding factor 2.
Autophagy facilitates the maintenance and restoration of gut microbiota homeostasis, and the autophagy-microbiota relationship has also been demonstrated in the pathophysiology of IBD. For instance, xenophagy has been proclaimed to modulate the gut microbiota in IBD. It has been argued that genes related to autophagy, including Atg7, P62, Atg16l1 and Irgm, are necessary for the maintenance of intestinal homeostasis through the activation of xenophagy (Shao et al., 2021).
Several studies have implicated epigenetics in IBD pathology, including miRNAs. miRNA is an endogenous non-coding small RNA that performs different biological functions by activating or silencing target genes through complementary pairing bonds involved in the regulation of gene expression. Many miRNAs are known to inhibit autophagy and target IBD-relevant autophagy genes (Nod2, Atg16l1 or Irgm), thereby modulating intestinal function and innate intestinal immunity and affecting inflammatory levels in IBD (Jung et al., 2021; S. Wang Shiyuan et al., 2018) (Table 1).
TABLE 1. miRNAs related with IBD pathology through modulation of autophagy. ATG16L1, autophagy-related protein 16-like protein 1; SQSTM1, Sequestosome 1; ATG5, autophagy-related gen; PTEN, Phosphatase and tensin homolog; NOD2, nucleotide binding oligomerization domain containing protein 2; NF-κB, Nuclear factor kappa-light-chain-enhancer; m mTOR, mammalian target of rapamycin; FOXO3, Forkhead box O3; SIAH2, E3 ubiquitin-protein ligase; SHIP1, inositol phosphatase; IRGM, immunity-related GTPase M; GSK3B, Glycogen synthase kinase-3 beta; VDR, vitamin D receptor; ORMDL3, Orosomucoid like 3; XBP1, X box-binding protein 1 spliced-1.
Relevance of autophagy in IBD fibrosis
Intestinal fibrosis is responsible for the high morbidity and surgical rates in patients with IBD. Although inflammation is essential for its initiation, anti-inflammatory treatments do not prevent fibrosis once it has started. Some patients, principally those with CD, develop fibrosis early, and this complication tends to reoccur following resection, whereas this is not observed in other types of patient (Lawrance et al., 2017). Fibrosis in IBD involves the accumulation of ECM components in the intestinal wall by activated cells of mesenchymal origin (fibroblasts, myofibroblasts and smooth muscle cells). ECM deposition is restricted to the superficial layers (mucosal and submucosal) in UC, while fibrosis in CD is located principally in the ileocecal valve and involves the whole bowel wall due to the transmural nature of the inflammation. The main promoters of intestinal fibrosis are soluble molecules (growth factors, and cytokines, of which TGFβ1 is considered a main player) released by activated immune and nonimmune cells, epithelial-to-mesenchymal transition (EMT) or endothelial-to-mesenchymal transition (EndoEMT), G protein-coupled receptors, and the gut microbiota (D’Alessio Silvia et al., 2022; D’Alessio S. et al., 2022). Various autophagy genes, including P62, ATG5, ATG7, ATG16l1 or ULK2, are associated with the regulation of TGFβ1 in lung fibrosis (Ghavami et al., 2018), but little is known about the role of TGFβ1 in the modulation of autophagy in IBD. The role of autophagy in IBD-related intestinal fibrosis is controversial. Many studies suggest it has a protective effect (Holvoet et al., 2017; Cosin-Roger et al., 2019), while others have pointed to the harmful role of excess autophagy in fibrotic processes (Yu et al., 2022). The following section will review the evidence for the role of autophagy in intestinal fibrosis at the genetic, cellular, and molecular levels.
Genetic and epigenetic basis of autophagy in intestinal fibrosis
Fibrostricture disease recurrence in some CD patients suggests the existence of a predisposing genetic background. Several studies have proposed the relevance of some single-nucleotide polymorphisms related with autophagy. The strongest fibrosis-autophagy association has been established between the variants of the CARD15/NOD2 gene (L1007fsinsC) and ATG16L1 (rs2241880). A fibrostricturing phenotype exhibits a strong association with the activation of autophagy by NOD2 and ATG16L1 in both pediatric and adult CD patients (Fowler et al., 2008; Strisciuglio et al., 2014). In infected cells, NOD2 and/or ATG16L1 mutations can alter the receptiveness of immune cells to bacteria, thus intensifying inflammatory signals that ultimately activate mesenchymal cells to produce ECM (Travassos et al., 2010). Myofibroblasts express NOD2 and ATG16L1 and, through the induction of caspase activation, enhance apoptosis (Luna, Masamunt, Lawrance, et al., 2011a). Apoptosis is responsible for reducing the number of myofibroblasts during fibrosis resolution, so the reduction in apoptosis of myofibroblasts could be extremely profibrotic.
Little is known about the role of miRNA-regulated autophagy in intestinal fibrosis. In neural cells, miRNA-200b activates apoptosis and suppresses autophagy by controlling the expression of the autophagy-related gene Ambra1 (Autophagy/Beclin1 regulator 1) (W. Huang et al., 2021). miRNA-200b has been postulated as a fibrotic biomarker in IBD, since it is overexpressed in the circulation of fibrostenotic CD patients and suppresses in vitro fibrosis by inhibiting the transdifferentiation of epithelial cells to myofibroblasts (Yingwei Chen et al., 2012). Alterations in collagen genes give rise to misfolded procollagen proteins which produce toxic aggregates in the ER that can induce ER stress and, consequently, autophagy. This process could be the ultimate cell-protection strategy used to reduce ER-accumulated cytotoxic aggregates in fibrotic tissue. (Del Principe et al., 2013). In IBD, a group of intestinal miRNAs (miRNA-150 (Ciccacci et al., 2016), miR-665 (M. Li Manying et al., 2017), miR-375 (Ambrose et al., 2012) and miR-346 (Guo et al., 2018) appear to modulate autophagy to regulate the unfolded protein response during the ER stress response, thereby promoting intestinal fibrosis in IBD (S. Wang Shu-Ling et al., 2018), though the underlying mechanisms require further validation.
Autophagy and cellular mediators of IBD fibrosis
The implication of autophagy in intestinal fibrosis is complicated, as it depends on the cell and the stage of the fibrotic process (fibrogenesis or ECM elimination) in question (Figure 3). Intestinal fibrogenesis is characterized by an accumulation of myofibroblasts (characterized in turn by the expression of α-smooth muscle actin (α-SMA) secretors of ECM proteins and/or an imbalance of proteins responsible for ECM degradation (matrix metalloproteinases (MMPs). Different cell populations, such as epithelial cells; endothelial cells; stellate cells, pericytes; bone marrow stem cells and resident mesenchymal cells (subepithelial myofibroblasts, smooth muscle cells, or fibroblasts) can transdifferentiate into myofibroblasts. The large number of ECM-producing cells in fibrotic tissues appears to be due to increased proliferation, reduced cell death and/or increased cell survival mediated by autophagy.
FIGURE 3. Findings concerning the role of autophagy in human intestinal fibrosis. The image reflects the pro-fibrotic and anti-fibrotic role of autophagy described in human intestinal samples, in function of the cell type (fibroblasts or epithelial cells) and the type of stimulus used to modulate autophagy. The figure also shows the fibrosis markers used to analyse the response. α-SMA, Alpha Smooth Muscle Actin; EMT, Epithelial Mesenchymal transition; MMP, Matrix Metalloproteinases; TGFβ1, Transforming Growth Factor beta 1; CTGF, Connective Tissue Growth Factor; FGF, Fibroblast Growth Factor.
Currently, the molecular and cellular study of autophagy in the fibrotic tissue of patients with IBD is very limited. Considering that the local mechanisms that maintain the progression of intestinal fibrosis are found in layers deep in the wall, it is preferable to analyse fibrotic intestinal resections before performing a biopsy. Our group (Ortiz-Masiá et al., 2014a) has described impaired autophagy in epithelial cells from the damaged mucosa of IBD patients; we observed a reduction of LC3II, an accumulation of P62 and mTOR proteins, and an increase in P62 staining in epithelial cells in affected tissue obtained from IBD resections. In support of our human data, decreased autophagy has been reported in preclinical models of intestinal fibrosis–the 2,4,6-Trinitrobenzene sulfonic acid (TNBS) model (Zeng et al., 2022) and Dextran sulphate sodium (DSS) model (Butera et al., 2022)—and in a heterologous transplant model (Cosin-Roger et al., 2019) (Table 2).
TABLE 2. Summary of the scientific evidence of the anti-fibrotic role of autophagy in IBD. HIF, human intestinal fibroblasts; UC; Ulcerative Colitis; CD, Crohn Disease; IBD, inflammatory bowel disease; TNBS, 2,4,6-Trinitrobenzene-1-sulfonic acid; DSS, Dextran sulfate sodium; TGFβ1, transforming growth factor beta 1; LC3, Microtubule-associated protein 1A/1B-light chain 3; mTOR, mammalian target of rapamycin; ATG, autophagy-related gen; ULK1, Unc-51-like kinase-1; ECM, extracellular matrix; FGF, Fibroblast Growth Factor; PARP, poly-ADP ribose polymerase; COL, collagen; TIMP, tissue inhibitors of metalloproteinases; MMP, metalloproteinases; ITGB6, integrin subunit beta 6; α-SMA, Alpha Smooth Muscle Actin; IL, interleukin; CTGF, Connective Tissue Growth Factor; EMT, epithelial mesenchymal transition; ERK, Ras-dependent extracellular signal-regulated kinase, SNAIL, zinc-finger transcription factor.
The intracellular elimination of collagen with the formation of new collagen-based extracellular matrices are necessary for tissue remodelling. In this context, the role of autophagy as a “weapon” to enhance collagen degradation in intestinal fibrosis has been demonstrated in several articles (Table 2). Cosin-Roger and collaborators showed the anti-fibrotic effect of autophagy stimulation in a murine heterotopic transplant model and in human fibroblasts (Cosin-Roger et al., 2019). In a similar way, the local inhibition of Rho kinases (ROCK) (proteins with multiple roles in TGFβ-induced myofibroblast activation) with AMA0825 increases autophagy in fibroblasts, facilitating a reduction in collagen and IL6 production and inhibiting myofibroblast transition (Holvoet et al., 2017) (Table 2). Other molecules with pro-autophagic activity and tested as anti-fibrotic therapeutic options in murine models of IBD include AC-73 and tocotrienols, described as inducers of apoptosis and autophagy. AC-73 is a specific inhibitor of CD147, an immunoglobulin implicated in liver (H.-Y. Li et al., 2015, 147) and intestinal fibrogenesis (Butera et al., 2022, 147) with potential as a marker of IBD in children (H. Wang et al., 2020, 147). On the other hand, tocotrienols, molecules related to vitamin E, have shown great efficiency in the in vitro activation of autophagy in intestinal fibroblasts. The treatment was shown to produce an improvement in anti-fibrotic markers in fibroblasts, thus favouring the resolution of fibrosis (Luna, Masamunt, Rickmann, et al., 2011b).
Other drugs in the pre-clinical phase capable of alleviating IBD by modulating autophagy are dapagliflozin and procyanidin A1. Dapagliflozin is a selective sodium-glucose co-transporter 2 inhibitor used for the management of type-2 diabetes mellitus. In the chronic murine TNBS model, dapagliflozin relieves colitis by increasing colonic autophagy and repressing apoptosis through activation of AMPK/mTOR and Nrf2/HO-1 pathways and suppression of the HMGB1/RAGE/NF-κB cascade (Arab, Al-Shorbagy, y Saad, 2021). Procyanidin A1 is a procyanidin (flavonoid) with antioxidant and anti-inflammatory effects. Procyanidin A1 alleviates acute DSS colitis by regulating AMPK/mTOR/p70S6K-mediated autophagy (H. Zhang et al., 2022)
Fibroblast autophagy in fibrotic disorders requires a fine balance, because an excessive autophagy favours cell survival and differentiation/activation (Del Principe et al., 2013). In this line, Yu and collaborators (Yu et al., 2022) have demonstrated the profibrotic role of autophagy as a mediator of the activation of intestinal fibroblasts (Table 3). Using a DSS fibrosis model and in vitro studies with primary intestinal fibroblasts, their work shows that Caveolin-1 (CAV1) increases the expression of SQSTM1/p62 and inhibits autophagy, thus preventing fibroblast transdifferentiation and avoiding the accumulation of α-SMA and ECM. Downregulation of CAV1 was observed in fibrotic resections of CD patients, suggesting that CAV1 deficiency induces fibroblast activation through indirect regulation of SQSTM1/p62, thereby promoting fibroblast autophagy. CAV1 is a recognised antifibrotic signalling mediator that inhibits the TGFβ1 signalling pathway in liver (J. Lu et al., 2018) and atrial (M. Zhang Sai-Long et al., 2020) fibrosis.
TABLE 3. Summary of the scientific evidence of the role of pro-fibrotic autophagy in IBD.
In recent years, the contribution of epithelial cells to the fibrotic process has been demonstrated in CD (Lovisa, Genovese, y Danese, 2019; Macias-Ceja et al., 2022; Ortiz-Masià et al., 2020) and UC (Wenxiu et al., 2021). In the TNBS fibrotic model, approximately one-third of (Fibroblast-specific protein 1) FSP1+ fibroblasts are derived from intestinal epithelial cells (Flier et al., 2010). Accumulated data regarding pulmonary fibrosis show that EMT transdifferentiation does not occur completely; rather, the EMT cells act as sources of soluble ligands that favor the transdifferentiation of fibroblasts (Hill et al., 2019; Yue et al., 2022). This phenomenon has also been observed in IBD by Zeng and group, who found that autophagy inhibited the induction of EMT in a HT-29 cell line, and that the co-culture induced fibroblast activation. In the DSS fibrotic model, EMT cells do not move and remain in the original anatomical position (Zeng et al., 2022). Specialised pro-resolving lipid mediators (lipoxin, resolvins, maresins, or protectins) are endogenous lipid autacoids that play a role in the resolution of inflammation, the progression of fibrosis and the regulation of the autophagy mechanism (Recchiuti et al., 2020). In this context, resolvin D1 has been proven to exert an anti-fibrotic effect in liver (J. Li et al., 2021) and intestinal (Zeng et al., 2022) fibrosis by modulating autophagy. In IBD, resolvin D1 reduces autophagy-induced EMT in intestinal epithelial cells and ameliorates intestinal fibrosis by disrupting epithelial–fibroblast crosstalk (Table 2).
Macrophage autophagy in fibrotic IBD
Various immune cells have been implicated in fibrosis, and among them macrophages play an important role in fibrosis and in the perpetuation of inflammation in the intestine (Ortiz-Masiá et al., 2014; Salvador et al., 2018; Lis-López et al., 2021; Macias-Ceja et al., 2022). Autophagy is also implicated in the innate immune response, as it is involved in the differentiation of monocytes into macrophages, in macrophage polarization, and in several of the immune functions of macrophages (Wen et al., 2022). Macrophages have traditionally been classified as two phenotypes: the pro-inflammatory (or classically activated) M1 macrophage and the anti-inflammatory (or alternatively activated) M2 phenotype, subclassified into M2a, M2b, M2c, and M2d. The macrophage phenotype is constantly changing and adapting in response to new environmental influences. In this context, autophagic control of macrophage polarization could be used as a therapeutic target in fibrosis. Evidence suggests that there is a relationship between the exacerbation of fibrosis, the type of macrophage polarization, and the chronicity of the inflammatory insult. Thus, M1 macrophages initiate the profibrotic process by releasing MMPs and CCL2 that promote EMT/EndoMT and fibrocyte recruitment. Proper functioning of macrophage autophagy is necessary to mitigate chronic inflammation by supressing proinflammatory M1 macrophage polarization (Wen et al., 2022). In the same way, the chronic and persistent activity of M2 macrophages, though tissue repairers, has been shown to favour the overproduction of TGFβ and growth factors that perpetuate the proliferation of myofibroblasts, the activation of EMT/EndoMT and the ECM deposit (Braga, Agudelo, and Camara, 2015).
Different studies suggest that changes in macrophage autophagy modulate the ability of these cells to promote intestinal fibrosis. Macrophages deficient in Atg16L1 show reduced autophagy, which favours the pro-inflammatory role of macrophages (Saitoh et al., 2008). The continued production of pro-inflammatory factors leads to chronic inflammation and, therefore, fibrosis. The murine model of heterotopic transplantation treated with 3-methyladenine (an autophagy inhibitor) favours the development of fibrosis, along with increased expression of proinflammatory mediators and a pro-fibrotic macrophage (CD16+), which accumulates in both the fibrotic TNBS model (Salvador et al., 2018) and in fibrotic CD samples (Macias-Ceja et al., 2022). CD16+ macrophages express M2 markers and are likely to be the producers of profibrotic cytokines (IL6, IL13, or IL8). Stimulation of autophagy with rapamycin in the murine model of heterotopic transplantation was found to increase the expression of anti-inflammatory mediators, and augmented the influx of macrophages with what seemed to be a regulatory/anti-inflammatory profile (Cosin-Roger et al., 2019). In a similar way, in the TNBS model of intestinal fibrosis, the anti-fibrotic effect of macrophages has been demonstrated, since the stimulation of autophagy favours the inhibition of the IL22/IL23 axis. (Mathur et al., 2019). Besides the traditional mediators classically associated with macrophage function, evidence shows the ability of macrophages to synthesize Wnt ligands in IBD patients. Macrophage-derived Wnt ligands have been shown to induce the EMT process (Macias-Ceja et al., 2022) and to undermine autophagy in the epithelial cells of IBD patients (Ortiz-Masiá et al., 2014).
Lessons from other organs: Role of autophagy in fibrotic diseases
There is extensive literature analysing the potential role of autophagy in different fibrotic diseases, such as the liver, lung, heart and kidney. All have one element in common, and that is the complex role of autophagy in the regulation and progression of fibrotic disease. Great strides have been made in characterizing the role of autophagy in fibrosis-related processes, such as cell signalling, elimination of misfolded proteins, lipid metabolism, and inflammation progression. When drawing conclusions about the pro-fibrotic or anti-fibrotic role of autophagy, it is necessary to consider the specific cell type analysed, the stimuli used, the experimental model, and the stage of the fibrosis process, and to differentiate autophagy-mediated effects from secondary compensatory actions. In the case of autophagy-mediated effects, we found evidence of how autophagy favours or prevents fibrogenesis by acting directly on cells/processes closely involved in the genesis of fibrosis (myofibroblasts, EMT, EndoEMT or fibroblasts). For example, some studies have shown that autophagy is involved in lipid droplet digestion and energy supply for fibroblast activation and may aggravate fibrosis. However, in the line of secondary compensatory effects we found evidence of cells/processes related to the control of chronic inflammation (cytokines, chemokines, growth factors or specialized pro-resolving lipid mediators released by immune and non-immune cells) which are responsible for orchestrating fibrosis processes. In this sense, some studies have shown that activated autophagy can attenuate inflammatory responses and ameliorate fibrosis in multiple organs. In the following section we will cite the main findings regarding the pro-fibrotic and anti-fibrotic role of autophagy in the development and perpetuation of fibrosis in other tissues, such as pulmonary, renal and hepatic fibrosis, areas in which research is more advanced.
Anti-fibrotic roles of autophagy in other fibrotic diseases
Among the mechanisms by which autophagy exerts a protective role we can cite lipid accumulation, RNA-binding proteins, anti-inflammatory effects, anti-aging effects, ECM clearance or the Microtubule-associated protein 1S/transcription factor EB (MAP1S/TFEB) pathway. In relation to liver fibrosis, different studies support that the activation of autophagy protects against fibrosis through different pathways, such as the promotion of lipid droplet regeneration, downregulation of pro-inflammatory cytokines in myofibroblasts, or the inhibition of epithelial stellate cell activation thorough upregulation of autophagy-related signalling pathways [Yes-associated protein (Ge et al., 2017), GATA binding protein 6 (Z. Zhang et al., 2017), MAP1S (W. Li et al., 2016) or class III phosphatidylinositol 3-kinase/homotypic fusion and protein sorting complex (Y. Li et al., 2020)]. Downregulation of MAP1S has been described in both hepatic and renal fibrotic tissue, and leads to autophagy-dependent impaired fibronectin clearance and fibronectin accumulation (Y. Li et al., 2020). In addition, the protective role of autophagy at the renal level has been demonstrated in other models, such as rapamycin, Beclin1 +/−, LC3−/−(Ding et al., 2014), ATG5-KO (Kimura et al., 2011) or ATG7-KO (Kawakami et al., 2015), where autophagy helps to control the accumulation of collagen and cytokines, cell infiltration, inhibition of EMT processes and reactive oxygen species clearance (Dai et al., 2022).
Numerous studies have shown that both autophagic function and autophagic flux are inhibited in idiopathic pulmonary fibrosis. Deficient autophagy in idiopathic pulmonary fibrosis inhibits fibroblast apoptosis (Romero et al., 2016; Wei, Sinha, y Levine, 2008) and promotes ECM deposition (Ricci et al., 2013; X. Zhang Xiaohuan et al., 2021), EMT/EndoEMT (Singh et al., 2015; Hill et al., 2019), myofibroblast transformation (Bernard et al., 2014; Im, Hergert, and Nho, 2015), and TGFβ1 signalling pathways (Patel et al., 2012; Ghavami et al., 2018). The protective role of the EB transcription factor, an inducer of autophagosome-lysosome fusion, has been demonstrated in both pulmonary and hepatic fibrosis. Overexpression of TFEB or trehalose treatment controls levels of inflammatory cytokines and prevents fibrosis-attenuating lysosol dysfunction. Currently, numerous drugs are authorized for the treatment of pulmonary fibrosis; although their exact mechanism of action is still not fully understood, it has been found that pirfenidone (Kurita et al., 2017) and nintedanib (Rangarajan et al., 2016) can activate autophagic activity in the fibrotic process.
Pro-fibrotic roles of autophagy in other fibrotic diseases
The detrimental effect of induced autophagy on fibrotic diseases has been widely demonstrated. The main mechanisms by which autophagy is believed to play a profibrotic role are processes such as lipid droplet digestion, non-coding RNAs, response to non-folded proteins, oxidative stress, or TGFβ/Smad pathway activation. In relation to hepatic fibrosis, there are several studies that have shown a link between autophagy activation and hepatic fibrosis, and they have highlighted the following affects: acceleration of the digestion of LDs as an energy source of epithelial stellate cells (Hernández-Gea et al., 2012); upregulation of the levels of several non-coding RNAs related with fibrosis (miR-96-5p, miR-29b, IncRNA XIST, IncRNA NEATI or IncRNA H19) (Y. Li et al., 2020); elevated formation of NLRP3 in epithelial stellate cells during oxidative stress; or mediation of fibrosis-related signalling pathways (PI3K/Akt/Mtor [(Y. Zhou et al., 2020), β-arrestinI/GSK-3β/SNAIL (Tan et al., 2019) or Platelet-derived growth factor-β/TGFβ/Smads (Yinghong Wang et al., 2019)]. Currently, the pro-fibrotic role of autophagy in the lung has been related with activated alveolar macrophages and the unfolded protein response. Macrophages might endorse the migration and proliferation of fibroblasts by activating autophagy, and bafilomycin A1 favours the unfolded protein response and ECM accumulation. Lastly, a pro-fibrotic role in renal tissue has been demonstrated in pharmacological models [chloroquine, rapamycin and 3-methyladenine) and in models with genetic deletions (ATG7-KO (Livingston et al., 2016), ATG5-KO (Baisantry et al., 2016) or mVps34-KO (J. Chen et al., 2013)]. Signalling pathways capable of altering autophagic markers (WNT/WISP1, Myc or CHOP) or autophagosome-lysosome fusion controllers (LAMP2) have been related to fibrotic processes in the kidney (Dai et al., 2022).
Conclusion and limitations
Intestinal fibrosis is the primary complication of IBD; however, it is also one of the least understood in terms of pathogenesis, and this affects diagnosis and treatment. Numerous studies clearly support the role of autophagy in IBD pathogenesis, and there is increasing evidence that it also plays a role in IBD progression, especially in fibrotic complications in CD patients. However, the evidence summarized herein highlights the controversial role of autophagy in the regulation and development of intestinal fibrosis, about which it is difficult to draw firm conclusions. The role of autophagy in the pathogenesis of intestinal fibrosis is multifactorial, and its biological effects (autophagy-mediated or secondary/compensatory) differ depending on the cell type, stimuli, and the stage of the fibrotic process or the fibrotic model used. Moreover, at present, intestinal fibrosis models do not meet the main characteristics of IBD-associated fibrosis, and most studies use chronic colitis models in mice, a species that is particularly resistant to fibrosis. Another limitation, related in this case to samples, is that very few studies to date have used human intestinal resections, and this is especially relevant considering that fibrosis develops mainly in the deeper layers in CD. Finally, different ways of monitoring autophagy have been employed in the studies we have reviewed, which constitutes a further hindrance to this field of research. Autophagy flux is considered a changing process, involving different stages. Therefore, changes in autophagy flux, as measured by LC3-II/LC3-I and LC3-II/P62 ratios, represent autophagy activity more adequately than autophagy marker expression, but require unified criteria to draw global conclusions about intestinal fibrosis.
Taken as a whole, emerging evidence confirms and advances our understanding of the role of autophagy in intestinal fibrosis. Most research supports the anti-fibrotic role of autophagy activation in intestinal fibrosis, and, though still a controversial topic, autophagy is increasingly viewed as a promising therapeutic target.
Currently, there are no antifibrotic therapies approved for IBD, but several molecules have shown promising results in preclinical studies, such the Rho kinase inhibitor AMA0825, resolving D1, dapagliflozin, procyanidin A1 and tocotrienols. These molecules may be involved in the antifibrotic effects mediated directly by autophagy (activating fibroblast autophagy and promoting collagen clearance, among others) or by secondary compensatory actions of autophagy (control of chronic inflammation, among others).
Author contributions
DO-M wrote this review. MB and DM-C revised this review. All authors contributed to the article and approved the submitted version.
Funding
This research was funded by grants from CIBEREHD, Instituto de Salud Carlos III (CB06/04/0071), Ministerio de Ciencia e Innovación (PID 2019-108996RB-I00), and Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital, Generalitat Valenciana (CIPROM 2021/044).
Acknowledgments
We thank Brian Normanly and Luis Alfonso Espinosa Ortega for their English language editing.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Ambrose, Monica, Moloney, Gerard, Heuston, Sinead, Rahman, Arman, Davies, Julie, Murphy, Carola, et al. (2012). Sa1870 MiR-375 is a key regulator of intestinal homeostasis in response to inflammatory stress. Gastroenterology 142–346. doi:10.1016/S0016-5085(12)61305-5
Arab, Hany H., Al-Shorbagy, Muhammad Y., and Saad, y. Muhammed A. (2021). Activation of autophagy and suppression of apoptosis by dapagliflozin attenuates experimental inflammatory bowel disease in rats: Targeting AMPK/MTOR, HMGB1/RAGE and Nrf2/HO-1 pathways. Chemico-Biological Interact. 335, 109368. doi:10.1016/j.cbi.2021.109368
Baisantry, Arpita, Bhayana, Sagar, Song, Rong, Ermeling, Esther, Wrede, Christoph, Jan, Hegermann, et al. (2016). Autophagy induces prosenescent changes in proximal tubular S3 segments. J. Am. Soc. Nephrol. JASN 27 (6), 1609–1616. doi:10.1681/ASN.2014111059
Bakke, Danika, and Sun, y. Jun (2018). Ancient nuclear receptor VDR with new functions: Microbiome and inflammation. Inflamm. Bowel Dis. 24 (6), 1149–1154. doi:10.1093/ibd/izy092
Barrett, Jeffrey C., Hansoul, Sarah, Nicolae, Dan L., Judy, H., Cho, Richard H. Duerr, John D. Rioux, Brant, Steven R., et al. (2008). Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat. Genet. 40 (8), 955–962. doi:10.1038/ng.175
Bernard, Monique, Dieudé, Mélanie, Yang, Bing, Hamelin, Katia, Underwood, Katy, and Marie-Josée Hébert, y. (2014). Autophagy fosters myofibroblast differentiation through MTORC2 activation and downstream upregulation of CTGF. Autophagy 10 (12), 2193–2207. doi:10.4161/15548627.2014.981786
Braga, Tarcio Teodoro, Agudelo, Juan Sebastian Henao, and Olsen Saraiva Camara, Niels (2015). Macrophages during the fibrotic process: M2 as friend and foe. Front. Immunol. 6, 602. doi:10.3389/fimmu.2015.00602
Brest, Patrick, Lapaquette, Pierre, Souidi, Mouloud, Kevin, Lebrigand, Cesaro, Annabelle, Vouret-Craviari, Valérie, et al. (2011). A synonymous variant in IRGM alters a binding site for MiR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn’s disease. Nat. Genet. 43 (3), 242–245. doi:10.1038/ng.762
Butera, Alessia, Teresa Quaranta, Maria, Crippa, Luca, Spinello, Isabella, Saulle, Ernestina, Di Carlo, Nazzareno, et al. (2022). CD147 targeting by AC-73 induces autophagy and reduces intestinal fibrosis associated with TNBS chronic colitis. J. Crohn’s Colitis 16, 1751–1761. doi:10.1093/ecco-jcc/jjac084
Ciccacci, Cinzia, Politi, Cristina, Novelli, Giuseppe, and Borgiani, y. Paola (2016). Advances in exploring the role of micrornas in inflammatory bowel disease. MicroRNA (Shariqah, United Arab. Emir. 5 (1), 5–11. doi:10.2174/2211536605666160111124812
Chatterji, Priya, Williams, Patrick A., Kelly A Whelan, Fernando C. Samper, Andres, Sarah F., Simon, Lauren A., Louis, R. Parham, et al. (2019). Posttranscriptional regulation of colonic epithelial repair by RNA binding protein IMP1/IGF2BP1. EMBO Rep. 20 (6), e47074. doi:10.15252/embr.201847074
Chen, Jianchun, Chen, Mystie X., Fogo, Agnes B., Harris, Raymond C., and Chen, y. Jian-Kang (2013a). MVps34 deletion in podocytes causes glomerulosclerosis by disrupting intracellular vesicle trafficking. J. Am. Soc. Nephrol. JASN 24 (2), 198–207. doi:10.1681/ASN.2012010101
Chen, Yingwei, Ge, Wensong, Xu, Leiming, Qu, Chunying, Zhu, Mingjie, Zhang, Wenzhu, et al. (2012). MiR-200b is involved in intestinal fibrosis of Crohn’s disease. Int. J. Mol. Med. 29 (4), 601–606. doi:10.3892/ijmm.2012.894
Chen, Yu, Wang, Chengxiao, Liu, Ying, Tang, Liwei, Zheng, Mingxia, Xu, Chundi, et al. (2013b). MiR-122 targets NOD2 to decrease intestinal epithelial cell injury in Crohn’s disease. Biochem. Biophysical Res. Commun. 438 (1), 133–139. doi:10.1016/j.bbrc.2013.07.040
Chen, Yunzi, Du, Jie, Zhang, Zhongyi, Liu, Tianjing, Shi, Yongyan, Ge, Xin, et al. (2014). MicroRNA-346 mediates tumor necrosis factor α-induced downregulation of gut epithelial vitamin D receptor in inflammatory bowel diseases. Inflamm. Bowel Dis. 20 (11), 1910–1918. doi:10.1097/MIB.0000000000000158
Chuang, Alice Y., Chuang, Jim C., Zhai, Zili, Wu, Feng, and Kwon, y. John H. (2014). NOD2 expression is regulated by MicroRNAs in colonic epithelial HCT116 cells. Inflamm. Bowel Dis. 20 (1), 126–135. doi:10.1097/01.MIB.0000436954.70596.9b
Cosin-Roger, Jesus, Canet, Francisco, DulceMacias-Ceja, C., Gisbert-Ferrándiz, Laura, Ortiz-Masiá, Dolores, Esplugues, Juan V., et al. (2019). Autophagy stimulation as a potential strategy against intestinal fibrosis. Cells 8 (9), 1078. doi:10.3390/cells8091078
Dai, Rong, Zhang, Lei, Jin, Hua, Wang, Dong, Cheng, Meng, Tian, Sang, et al. (2022). Autophagy in renal fibrosis: Protection or promotion? Front. Pharmacol. 13, 963920. doi:10.3389/fphar.2022.963920
D’Alessio, S., Ungaro, F., Noviello, D., Lovisa, S., Peyrin-Biroulet, L., and y Danese, S. (2022b). Revisiting fibrosis in inflammatory bowel disease: The gut thickens. Nat. Rev. Gastroenterology Hepatology 19 (3), 169–184. doi:10.1038/s41575-021-00543-0
D’Alessio, Silvia, Federica Ungaro, , Noviello, Daniele, Lovisa, Sara, Peyrin-Biroulet, Laurent, and Silvio Danese, y. (2022a). Revisiting fibrosis in inflammatory bowel disease: The gut thickens. Nat. Rev. Gastroenterology Hepatology 19 (3), 169–184. doi:10.1038/s41575-021-00543-0
Del Principe, , Domenico, Pasquale Lista, Walter, Malorni, and Anna Maria Giammarioli, y. (2013). Fibroblast autophagy in fibrotic disorders. J. Pathology 229 (2), 208–220. doi:10.1002/path.4115
D’Haens, Geert, Rieder, Florian, Feagan, Brian G., Higgins, Peter D. R., Panés, Julian, Maaser, Christian, et al. (2022). Challenges in the pathophysiology, diagnosis, and management of intestinal fibrosis in inflammatory bowel disease. Gastroenterology 162 (1), 26–31. doi:10.1053/j.gastro.2019.05.072
Ding, Yan, SungKim, ll, Lee, So-Young, Koo, Ja Kun, Wang, Zhibo, and Choi, y. Mary E. (2014). Autophagy regulates TGF-β expression and suppresses kidney fibrosis induced by unilateral ureteral obstruction. J. Am. Soc. Nephrol. JASN 25 (12), 2835–2846. doi:10.1681/ASN.2013101068
Flier, Sarah N., Tanjore, Harikrishna, Kokkotou, Efi G., Sugimoto, Hikaru, Zeisberg, Michael, and Kalluri, y. Raghu (2010). Identification of epithelial to mesenchymal transition as a novel source of fibroblasts in intestinal fibrosis. J. Biol. Chem. 285 (26), 20202–20212. doi:10.1074/jbc.M110.102012
Foerster, Elisabeth G., MukherjeeCabral-Fernandes, Liliane, JulianaRocha, D. B., Rocha, J. D. B., Girardin, S. E., Philpott, D. J., et al. (2022). How autophagy controls the intestinal epithelial barrier. Autophagy 18 (1), 86–103. doi:10.1080/15548627.2021.1909406
Fowler, Elizabeth V., James, Doecke, Simms, Lisa A., Zhao, Zhen, Webb, Penelope M., Hayward, Nicholas K., et al. (2008). ATG16L1 T300A shows strong associations with disease subgroups in a large Australian IBD population: Further support for significant disease heterogeneity. Am. J. Gastroenterology 103 (10), 2519–2526. doi:10.1111/j.1572-0241.2008.02023.x
Gardet, Agnès, Yair, Benita, Chun, Li, Sands, Bruce E., Ballester, Isabel, Stevens, Christine, et al. (2010). LRRK2 is involved in the IFN-gamma response and host response to pathogens. J. Immunol. Baltim. Md. 1950) 185 (9), 5577–5585. doi:10.4049/jimmunol.1000548
Ge, Maoxu, Liu, Hong, Zhang, Yixuan, Li, Naren, Zhao, Shuangshuang, Zhao, Wuli, et al. (2017). The anti-hepatic fibrosis effects of dihydrotanshinone I are mediated by disrupting the yes-associated protein and transcriptional enhancer factor D2 complex and stimulating autophagy. Br. J. Pharmacol. 174 (10), 1147–1160. doi:10.1111/bph.13766
Ghavami, Saeid, Yeganeh, Behzad, Zeki, Amir A., Shojaei, Shahla, Kenyon, Nicholas J., Ott, Sean, et al. (2018). Autophagy and the unfolded protein response promote profibrotic effects of TGF-ß1 in human lung fibroblasts. Am. J. Physiology Lung Cell. Mol. Physiology 314 (3), L493–L504. doi:10.1152/ajplung.00372.2017
Guo, Junfei, Yang, Zhen, Yang, Xi, Tong, Li, Liu, Min, and Tang, y. Hua (2018). MiR-346 functions as a pro-survival factor under ER stress by activating mitophagy. Cancer Lett. 413, 69–81. doi:10.1016/j.canlet.2017.10.030
Hampe, Jochen, Franke, Andre, Rosenstiel, Philip, Till, Andreas, Teuber, Markus, Huse, Klaus, et al. (2007). A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for crohn disease in ATG16L1. Nat. Genet. 39 (2), 207–211. doi:10.1038/ng1954
Henckaerts, Liesbet, Cleynen, Isabelle, Brinar, Marko, John, Jestinah Mahachie, Kristel Van Steen, , Paul, Rutgeerts, et al. (2011). Genetic variation in the autophagy gene ULK1 and risk of Crohn’s disease. Inflamm. Bowel Dis. 17 (6), 1392–1397. doi:10.1002/ibd.21486
Hernández-Gea, Virginia, Ghiassi-Nejad, Zahra, Rozenfeld, Raphael, Gordon, Ronald, Fiel, Maria Isabel, Yue, Zhenyu, et al. (2012). Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. Gastroenterology 142 (4), 938–946. doi:10.1053/j.gastro.2011.12.044
Hill, Charlotte, Li, Juanjuan, Liu, Dian, Franco, Conforti, Brereton, Christopher J., Yao, Liudi, et al. (2019). Autophagy inhibition-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis. Cell Death Dis. 10 (8), 591. doi:10.1038/s41419-019-1820-x
Holvoet, Tom, Devriese, Sarah, Castermans, Karolien, Boland, Sandro, Leysen, Dirk, Vandewynckel, Yves-Paul, et al. (2017). Treatment of intestinal fibrosis in experimental inflammatory bowel disease by the pleiotropic actions of a local Rho kinase inhibitor. Gastroenterology 153 (4), 1054–1067. doi:10.1053/j.gastro.2017.06.013
Hu, Xiaoming, Deng, Jiali, Yu, Tianming, Chen, Shanghai, Ge, Yadong, Zhou, Ziheng, et al. (2019). ATF4 deficiency promotes intestinal inflammation in mice by reducing uptake of glutamine and expression of antimicrobial peptides. Gastroenterology 156 (4), 1098–1111. doi:10.1053/j.gastro.2018.11.033
Huang, Wanqi, Huang, Tianchu, Liu, Yusi, Fu, Jialin, Wei, Xiaowei, Liu, Dan, et al. (2021). Nuclear factor I-C disrupts cellular homeostasis between autophagy and apoptosis via miR-200b-Ambra1 in neural tube defects. Cell Death Dis. 13 (1), 17. doi:10.1038/s41419-021-04473-2
Huang, Xin, Shen, Yulei, Liu, Miao, Bi, Chengfeng, Jiang, Chunsun, Iqbal, Javeed, et al. (2012). Quantitative proteomics reveals that MiR-155 regulates the PI3K-akt pathway in diffuse large B-cell lymphoma. Am. J. Pathology 181 (1), 26–33. doi:10.1016/j.ajpath.2012.03.013
Hugot, J. P., Chamaillard, M., Zouali, H., Lesage, S., Cézard, J. P., Belaiche, J., et al. (2001). Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 411 (6837), 599–603. doi:10.1038/35079107
Im, Jintaek, Hergert, Polla, and Richard Seonghun Nho, y. (2015). Reduced FoxO3a expression causes low autophagy in idiopathic pulmonary fibrosis fibroblasts on collagen matrices. Am. J. Physiology. Lung Cell. Mol. Physiology 309 (6), L552–L561. doi:10.1152/ajplung.00079.2015
Jung, HyunTaek, Kim, Jae Seok, Hwa Lee, Keum, Tizaoui, Kalthoum, Terrazzino, Salvatore, Cargnin, Sarah, et al. (2021). Roles of MicroRNAs in inflammatory bowel disease. Int. J. Biol. Sci. 17 (8), 2112–2123. doi:10.7150/ijbs.59904
Karimi, Sara, Tabataba-Vakili, Sanam, Yari, Zahra, Alborzi, Forough, Hedayati, Mehdi, Ebrahimi-Daryani, Nasser, et al. (2019). The effects of two vitamin D regimens on ulcerative colitis activity index, quality of life and oxidant/anti-oxidant status. Nutr. J. 18 (1), 16. doi:10.1186/s12937-019-0441-7
Kawakami, Takahisa, Gomez, Ivan G., Ren, Shuyu, Kelly, Hudkins, Roach, Allie, Alpers, Charles E., et al. (2015). Deficient autophagy results in mitochondrial dysfunction and FSGS. J. Am. Soc. Nephrol. JASN 26 (5), 1040–1052. doi:10.1681/ASN.2013111202
Kim, Hye-Youn, Hyeok, Yi Kwon, Huyen, Trang Ha Thi, HoLee, Jae, Kim, Gwang Il, Hahm, Ki-Baek, et al. (2016). MicroRNA-132 and MicroRNA-223 control positive feedback circuit by regulating FOXO3a in inflammatory bowel disease. J. Gastroenterology Hepatology 31 (10), 1727–1735. doi:10.1111/jgh.13321
Kimura, Tomonori, Takabatake, Yoshitsugu, Takahashi, Atsushi, Kaimori, Jun-ya, Matsui, Isao, Namba, Tomoko, et al. (2011). Autophagy protects the proximal tubule from degeneration and acute ischemic injury. J. Am. Soc. Nephrol. JASN 22 (5), 902–913. doi:10.1681/ASN.2010070705
Kishi-Itakura, Chieko, Koyama-Honda, Ikuko, Itakura, Eisuke, and Mizushima, Noboru (2014). Ultrastructural analysis of autophagosome organization using mammalian autophagy-deficient cells. J. Cell Sci. 127 (18), 4089–4102. doi:10.1242/jcs.156034
Kurita, Yusuke, Araya, Jun, Minagawa, Shunsuke, Hara, Hiromichi, Ichikawa, Akihiro, Saito, Nayuta, et al. (2017). Pirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy. Respir. Res. 18 (1), 114. doi:10.1186/s12931-017-0600-3
Law, Arjun Datt, Dutta, Usha, Kochhar, Rakesh, Vaishnavi, Chetana, Kumar, Shiva, Noor, Talha, et al. (2019). Vitamin D deficiency in adult patients with ulcerative colitis: Prevalence and relationship with disease severity, extent, and duration. Indian J. Gastroenterology Official J. Indian Soc. Gastroenterology 38 (1), 6–14. doi:10.1007/s12664-019-00932-z
Lawrance, Ian C., Rogler, Gerhard, Bamias, Giorgos, Breynaert, Christine, Florholmen, Jon, Pellino, Gianluca, et al. (2017). Cellular and molecular mediators of intestinal fibrosis. J. Crohn’s Colitis 11 (12), 1491–1503. doi:10.1016/j.crohns.2014.09.008
Li, Hai-Yan, Ju, Di, Zhang, Da-Wei, Li, Hao, Kong, Ling-Min, Guo, Yanhai, et al. (2015). Activation of TGF-ß1-cd147 positive feedback loop in hepatic stellate cells promotes liver fibrosis. Sci. Rep. 5, 16552. doi:10.1038/srep16552
Li, Jiahuan, Deng, Xiaoling, Wang, Shuhan, Jiang, Qianqian, and Xu, Keshu (2021). Resolvin D1 attenuates CCl4 induced liver fibrosis by inhibiting autophagy-mediated HSC activation via AKT/MTOR pathway. Front. Pharmacol. 12, 792414. doi:10.3389/fphar.2021.792414
Li, Manying, Zhang, Shenghong, Qiu, Yun, Yao, He, Chen, Baili, Ren, Mao, et al. (2017a). Upregulation of MiR-665 promotes apoptosis and colitis in inflammatory bowel disease by repressing the endoplasmic reticulum stress components XBP1 and ORMDL3. Cell Death Dis. 8 (3), e2699. doi:10.1038/cddis.2017.76
Li, Nana, Yuan, Miao, Shan, Yujia, Liu, Bing, Yang, Li, Zhao, Lifen, et al. (2017b). MiR-106b and MiR-93 regulate cell progression by suppression of PTEN via PI3K/akt pathway in breast cancer. Cell Death Dis. 8 (5), e2796. doi:10.1038/cddis.2017.119
Li, Wenjiao, Zou, Jing, Yue, Fei, Song, Kun, Chen, Qi, Wallace, L., et al. (2016). Defects in MAP1S-mediated autophagy cause reduction in mouse lifespans especially when fibronectin is overexpressed. Aging Cell 15 (2), 370–379. doi:10.1111/acel.12441
Li, Yajing, Liu, Runping, Wu, Jianzhi, and Li, Xiaojiaoyang (2020). Self-Eating: Friend or foe? The emerging role of autophagy in fibrotic diseases. Theranostics 10 (18), 7993–8017. doi:10.7150/thno.47826
Lis-López, Lluis, Bauset, Cristina, Seco-Cervera, Marta, and Cosín-Roger, Jesús (2021). Is the macrophage phenotype determinant for fibrosis development? » Biomed. 9 (12), 1747. doi:10.3390/biomedicines9121747
Liu, L., He, J., Wei, X., Wan, G., Lao, Y., Xu, W., et al. (2017). MicroRNA-20a-Mediated loss of autophagy contributes to breast tumorigenesis by promoting genomic damage and instability. Oncogene 36 (42), 5874–5884. doi:10.1038/onc.2017.193
Livingston, Man J., Han-Fei, Ding, Shuang, Huang, Joseph A, Hill, Xiao-Ming, Yin, and Zheng, Dong (2016). Persistent activation of autophagy in kidney tubular cells promotes renal interstitial fibrosis during unilateral ureteral obstruction. Autophagy 12 (6), 976–998. doi:10.1080/15548627.2016.1166317
Lovisa, Sara, Genovese, Giannicola, and Danese, Silvio (2019). Role of epithelial-to-mesenchymal transition in inflammatory bowel disease. J. Crohn’s Colitis 13 (5), 659–668. doi:10.1093/ecco-jcc/jjy201
Lu, Changming, Chen, Jianfeng, Xu, Hua-Guo, Zhou, Xianzheng, He, Qiongqiong, Li, Yu-Lin, et al. (2014). MIR106B and MIR93 prevent removal of bacteria from epithelial cells by disrupting atg16l1-mediated autophagy. Gastroenterology 146 (1), 188–199. doi:10.1053/j.gastro.2013.09.006
Lu, Jing, Zhang, Jie, Wang, Yan, and Sun, Quan (2018). Caveolin-1 scaffolding domain peptides alleviate liver fibrosis by inhibiting TGF-ß1/smad signaling in mice. Int. J. Mol. Sci. 19 (6), 1729. doi:10.3390/ijms19061729
Luna, Jeroni, Carme Masamunt, Maria, Lawrance, Ian Craig, and Sans, Miquel (2011a). Mesenchymal cell proliferation and programmed cell death: Key players in fibrogenesis and new targets for therapeutic intervention. Am. J. Physiology. Gastrointest. Liver Physiology 300 (5), G703–G708. doi:10.1152/ajpgi.00504.2010
Luna, Jeroni, Carme Masamunt, Maria, Rickmann, Mariana, Mora, Rut, España, Carolina, Delgado, Salvadora, et al. (2011b). Tocotrienols have potent antifibrogenic effects in human intestinal fibroblasts. Inflamm. Bowel Dis. 17 (3), 732–741. doi:10.1002/ibd.21411
Mathur, Ramkumar, Alam, Mahabub Maraj, Zhao, Xiao-Feng, Liao, Yuan, Shen, Jeffrey, Shannon, Morgan, et al. (2019). Induction of autophagy in Cx3cr1+ mononuclear cells limits IL-23/IL-22 axis-mediated intestinal fibrosis. Mucosal Immunol. 12 (3), 612–623. doi:10.1038/s41385-019-0146-4
Macias-Ceja Dulce, C., Sandra, Coll, Cristina, Bauset, Seco-Cervera, Marta, Gisbert-Ferrándiz, Laura, Navarro, Francisco, et al. (2022). Ifnγ-treated macrophages induce EMT through the WNT pathway: Relevance in Crohn’s disease. Biomedicines 10 (5), 1093. doi:10.3390/biomedicines10051093
McCarroll, Steven A., Huett, Alan, Kuballa, Petric, Chilewski, Shannon D., Landry, Aimee, Goyette, Philippe, et al. (2008). Deletion polymorphism upstream of IRGM associated with altered IRGM expression and Crohn’s disease. Nat. Genet. 40 (9), 1107–1112. doi:10.1038/ng.215
Mizushima, N., Noda, T., Yoshimori, T., Tanaka, Y., Ishii, T., George, M. D., et al. (1998). A protein conjugation system essential for autophagy. Nature 395 (6700), 395–398. doi:10.1038/26506
Mizushima, Noboru (2018). A brief history of autophagy from cell biology to physiology and disease. Nat. Cell Biol. 20 (5), 521–527. doi:10.1038/s41556-018-0092-5
Mizushima, Noboru, Levine, Beth, Ana Maria Cuervo, , and Klionsky, y. Daniel J. (2008). Autophagy fights disease through cellular self-digestion. Nature 451 (7182), 1069–1075. doi:10.1038/nature06639
Nata, Toshie, Fujiya, Mikihiro, Ueno, Nobohiro, Moriichi, Kentaro, Konishi, Hiroaki, Tanabe, Hiroki, et al. (2013). MicroRNA-146b improves intestinal injury in mouse colitis by activating nuclear factor-?b and improving epithelial barrier function. J. Gene Med. 15 (6-7), 249–260. doi:10.1002/jgm.2717
Ng, Siew C., Shi, Hai Yun, Hamidi, Nima, Underwood, Fox E., Tang, Whitney, Benchimol, Eric I., et al. (2017). Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet (London, Engl. 390 (10114), 2769–2778. doi:10.1016/S0140-6736(17)32448-0
Nguyen, Hang Thi Thu, Dalmasso, Guillaume, Müller, Stefan, Carrière, Jessica, Frank, Seibold, and Darfeuille-Michaud, Arlette (2014). Crohn’s disease-associated adherent invasive Escherichia coli modulate levels of MicroRNAs in intestinal epithelial cells to reduce autophagy. Gastroenterology 146 (2), 508–519. doi:10.1053/j.gastro.2013.10.021
Ogura, Y., Bonen, D. K., Inohara, N., Nicolae, D. L., Chen, F. F., Ramos, R., et al. (2001). A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 411 (6837), 603–606. doi:10.1038/35079114
Ortiz-Masiá, D., Cosín-Roger, J., Calatayud, S., Hernández, C., Alós, R., Hinojosa, J., et al. (2014a). Hypoxic macrophages impair autophagy in epithelial cells through Wnt1: Relevance in IBD. Mucosal Immunol. 7 (4), 929–938. doi:10.1038/mi.2013.108
Ortiz-Masià, Dolores, Salvador, Pedro, DulceMacias-Ceja, C., Gisbert-Ferrándiz, Laura, Esplugues, Juan V., Manyé, Josep, et al. (2020). WNT2b activates epithelial-mesenchymal transition through FZD4: Relevance in penetrating Crohn´s disease. J. Crohn’s Colitis 14 (2), 230–239. doi:10.1093/ecco-jcc/jjz134
Parkes, Miles, Barrett, Jeffrey C. Natalie J. Prescott, Mark, Tremelling, Anderson, Carl A., Fisher, Sheila A., Roberts, Roland G., et al. (2007). Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn’s disease susceptibility. Nat. Genet. 39 (7), 830–832. doi:10.1038/ng2061
Patel, Avignat S., Lin, Ling, Geyer, Alexander, Haspel, Jeffrey A., Chang, Hyeok An, Cao, Jiaofei, et al. (2012). Autophagy in idiopathic pulmonary fibrosis. PloS One 7 (7), e41394. doi:10.1371/journal.pone.0041394
Pierdomenico, Maria, Cesi, Vincenzo, Cucchiara, Salvatore, Vitali, Roberta, Prete, Enrica, Costanzo, Manuela, et al. (2016). NOD2 is regulated by mir-320 in physiological conditions but this control is altered in inflamed tissues of patients with inflammatory bowel disease. Inflamm. Bowel Dis. 22 (2), 315–326. doi:10.1097/MIB.0000000000000659
Rangarajan, Sunad, Kurundkar, Ashish, Kurundkar, Deepali, Bernard, Karen, Sanders, Yan Y., Ding, Qiang, et al. (2016). Novel mechanisms for the antifibrotic action of nintedanib. Am. J. Respir. Cell Mol. Biol. 54 (1), 51–59. doi:10.1165/rcmb.2014-0445OC
Recchiuti, Antonio, Isopi, Elisa, Romano, Mario, and Mattoscio, y. Domenico (2020). Roles of specialized pro-resolving lipid mediators in autophagy and inflammation. Int. J. Mol. Sci. 21 (18), 6637. doi:10.3390/ijms21186637
Reyes, Ramirez, Josué, M. J., Cuesta, Rafael, and Pause, y. Arnim (2021). Folliculin: A regulator of transcription through AMPK and mtor signaling pathways. Front. Cell Dev. Biol. 9, 667311. doi:10.3389/fcell.2021.667311
Ricci, Alberto, Cherubini, Emanuela, Scozzi, Davide, Pietrangeli, Vittorio, Tabbì, Luca, Raffa, Salvatore, et al. (2013). Decreased expression of autophagic Beclin 1 protein in idiopathic pulmonary fibrosis fibroblasts. J. Cell. Physiology 228 (7), 1516–1524. doi:10.1002/jcp.24307
Rioux, John D., Ramnik, J., Xavier, Kent D., Goyette, Philippe, Huett, Alan, Green, Todd, et al. (2007). Genome-wide association study identifies new susceptibility loci for crohn disease and implicates autophagy in disease pathogenesis. Nat. Genet. 39 (5), 596–604. doi:10.1038/ng2032
Romero, Yair, Bueno, Marta, Ramirez, Remedios, Álvarez, Diana, Sembrat, John C., Goncharova, Elena A., et al. (2016). MTORC1 activation decreases autophagy in aging and idiopathic pulmonary fibrosis and contributes to apoptosis resistance in IPF fibroblasts. Aging Cell 15 (6), 1103–1112. doi:10.1111/acel.12514
Rouquette-Jazdanian, , Alexandre, K., Kortum, Robert L., Li, Wenmei, Merrill, Robert K., Nguyen, Phan H., et al. (2015). MiR-155 controls lymphoproliferation in LAT mutant mice by restraining T-cell apoptosis via SHIP-1/MTOR and PAK1/FOXO3/BIM pathways. PloS One 10 (6), e0131823. doi:10.1371/journal.pone.0131823
Saitoh, Tatsuya, Fujita, Naonobu, Jang, Myoung Ho, Uematsu, Satoshi, Yang, Bo-Gie, Satoh, Takashi, et al. (2008). Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature 456 (7219), 264–268. doi:10.1038/nature07383
Salvador, Pedro, Macías-Ceja, Dulce Carolina, Gisbert-Ferrándiz, Laura, Hernández, Carlos, Bernardo, David, Alós, Rafael, et al. (2018). CD16+ macrophages mediate fibrosis in inflammatory bowel disease. J. Crohn’s Colitis 12 (5), 589–599. doi:10.1093/ecco-jcc/jjx185
Shao, Bo-Zong, Yao, Yi, Zhai, Jun-Shan, Zhu, Jian-Hua, Li, Jin-Ping, and Wu, Kai (2021). The role of autophagy in inflammatory bowel disease. Front. Physiology 12, 621132. doi:10.3389/fphys.2021.621132
Shen, Tong, Shi, Li, Cai, Ling-Dong, Liu, Jing-Lin, Wang, Chu-Yi, Gan, Wen-Juan, et al. (2018). Erbin exerts a protective effect against inflammatory bowel disease by suppressing autophagic cell death. Oncotarget 9 (15), 12035–12049. doi:10.18632/oncotarget.23925
Singh, Krishna K., Lovren, Fina, Pan, Yi, Quan, Adrian, Ramadan, Azza, Matkar, Pratiek N., et al. (2015). The essential autophagy gene ATG7 modulates organ fibrosis via regulation of endothelial-to-mesenchymal transition. J. Biol. Chem. 290 (5), 2547–2559. doi:10.1074/jbc.M114.604603
Strisciuglio, Caterina, Auricchio, Renata, Martinelli, Massimo, Staiano, Annamaria, Giugliano, Francesca Paola, Andreozzi, Marialuisa, et al. (2014). Autophagy genes variants and paediatric Crohn’s disease phenotype: A single-centre experience. Dig. Liver Dis. Official J. Italian Soc. Gastroenterology Italian Assoc. Study Liver 46 (6), 512–517. doi:10.1016/j.dld.2014.02.016
Tan, Siwei, Lu, Yu, Xu, Minyi, Huang, Xiaoli, Liu, Huiling, Jiang, Jie, et al. (2019). β-Arrestin1 enhances liver fibrosis through autophagy-mediated snail signaling. FASEB J. Official Publ. Fed. Am. Soc. Exp. Biol. 33 (2), 2000–2016. doi:10.1096/fj.201800828RR
Travassos, Leonardo H., Carneiro, Leticia A. M., Ramjeet, Mahendrasingh, Hussey, Seamus, Kim, Yun-Gi, Magalhães, João G., et al. (2010). Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat. Immunol. 11 (1), 55–62. doi:10.1038/ni.1823
Wang, Hongli, Ye, Jun, Liu, Ruitao, Chen, Guanhua, Zhao, Junhong, Huang, Ling, et al. (2020). Clinical significance of CD147 in children with inflammatory bowel disease. BioMed Res. Int. 2020, 7647181. doi:10.1155/2020/7647181
Wang, Shiyuan, Huang, Yan, Zhou, Cili, Wu, Huangan, Zhao, Jimeng, Wu, Luyi, et al. (2018a). The role of autophagy and related MicroRNAs in inflammatory bowel disease. Gastroenterology Res. Pract. 2018, 7565076–7565110. doi:10.1155/2018/7565076
Wang, Shu-Ling, Shao, Bo-Zong, Zhao, Sheng-Bing, Fang, Jun, Gu, Lun, Miao, Chao-Yu, et al. (2018b). Impact of Paneth cell autophagy on inflammatory bowel disease. Front. Immunol. 9, 693. doi:10.3389/fimmu.2018.00693
Wang, Yinghong, Sun, Yancai, Zuo, Longquan, Wang, Yanan, and Huang, y. Yan (2019). ASIC1a promotes high glucose and PDGF-induced hepatic stellate cell activation by inducing autophagy through CaMKKβ/ERK signaling pathway. Toxicol. Lett. 300, 1–9. doi:10.1016/j.toxlet.2018.10.003
Wang, Yuqiong, Zhang, Xiyu, Tang, Wei, Lin, Zhenghong, Xu, Limei, Dong, Ruifen, et al. (2017). MiR-130a upregulates MTOR pathway by targeting TSC1 and is transactivated by NF-?b in high-grade serous ovarian carcinoma. Cell Death Differ. 24 (12), 2089–2100. doi:10.1038/cdd.2017.129
Wei, Yongjie, Sinha, Sangita, and Levine, y. Beth (2008). Dual role of JNK1-mediated phosphorylation of bcl-2 in autophagy and apoptosis regulation. Autophagy 4 (7), 949–951. doi:10.4161/auto.6788
Wen, Jun-Hao, Li, Dong-Yi, Liang, Shan, Yang, Chen, Tang, Ji-Xin, and Liu, y. Hua-Feng (2022). Macrophage autophagy in macrophage polarization, chronic inflammation and organ fibrosis. Front. Immunol. 13, 946832. doi:10.3389/fimmu.2022.946832
Wenxiu, Jia, Yang, Mingyue, Han, Fei, Luo, Yuxin, Wu, Mengyao, Li, Chenyang, et al. (2021). Effect and mechanism of TL1A expression on epithelial-mesenchymal transition during chronic colitis-related intestinal fibrosis. Mediat. Inflamm. 2021, 5927064. doi:10.1155/2021/5927064
Wu, Ming-Yue, Le Liu, , Wang, Er-Jin, Xiao, Hai-Tao, Cai, Cui-Zan, Wang, Jing, et al. (2021). PI3KC3 complex subunit NRBF2 is required for apoptotic cell clearance to restrict intestinal inflammation. Autophagy 17 (5), 1096–1111. doi:10.1080/15548627.2020.1741332
Yu, Mengli, Zhu, Wei, Wang, Jinhai, Chen, Xueyang, He, Xinjue, Lin, Bingru, et al. (2022). Caveolin-1 alleviates Crohn’s disease–induced intestinal fibrosis by inhibiting fibroblasts autophagy through modulating sequestosome 1. Inflamm. Bowel Dis. 28 (6), 923–935. doi:10.1093/ibd/izab342
Yue, Yue-Liang, Zhang, Meng-Yu, Liu, Jian-Yu, Fang, Li-Jun, and Qu, y. Yi-Qing (2022). The role of autophagy in idiopathic pulmonary fibrosis: From mechanisms to therapies. Ther. Adv. Respir. Dis. 16, 17534666221140972. doi:10.1177/17534666221140972
Zachari, Maria, and Ganley, y. Ian G. (2017). The mammalian ULK1 complex and autophagy initiation. Essays Biochem. 61 (6), 585–596. doi:10.1042/EBC20170021
Zeng, Cui, Liu, Xinghuang, Xiong, Danping, Zou, Kaifang, and Bai, y. Tao (2022). Resolvin D1 prevents epithelial-to-mesenchymal transition and reduces collagen deposition by stimulating autophagy in intestinal fibrosis. Dig. Dis. Sci. 67 (10), 4749–4759. doi:10.1007/s10620-021-07356-w
Zhai, Zili, Wu, Feng, Dong, Fengshi, AliceChuang, Y., Messer, Jeannette S., Boone, David L., et al. (2014). Human autophagy gene ATG16L1 is post-transcriptionally regulated by mir142-3p. Autophagy 10 (3), 468–479. doi:10.4161/auto.27553
Zhang, Haihua, Lang, Wuying, Liu, Xin, Bai, Jiangsong, Jia, Qinghui, and Shi, y. Qiumei (2022). Procyanidin A1 alleviates DSS-induced ulcerative colitis via regulating AMPK/MTOR/P70S6K-mediated autophagy. J. Physiology Biochem. 78 (1), 213–227. doi:10.1007/s13105-021-00854-5
Zhang, Meixia, Wang, Hechuan, Wang, Xiaowen, Bie, Mengjun, Lu, Kai, and Xiao, y. Hua (2020a). MG53/CAV1 regulates transforming growth factor-ß1 signaling-induced atrial fibrosis in atrial fibrillation. Cell CycleGeorget. Tex.) 19 (20), 2734–2744. doi:10.1080/15384101.2020.1827183
Zhang, Sai-Long, Zhi-Yong, Li, Wang, Dong-Sheng, Xu, Tian-Ying, Fan, Mao-Bing, Cheng, Ming-He, et al. (2020b). Aggravated ulcerative colitis caused by intestinal Metrnl deficiency is associated with reduced autophagy in epithelial cells. Acta Pharmacol. Sin. 41 (6), 763–770. doi:10.1038/s41401-019-0343-4
Zhang, Wen-Juan, Chen, Shu-Juan, Zhou, Shun-Chang, Wu, Su-Zhen, and Wang, Hui (2021a). Inflammasomes and fibrosis. Front. Immunol. 12, 643149. doi:10.3389/fimmu.2021.643149
Zhang, Xiaohuan, Mao, Yanwen, Peng, Wei, Liu, Huiming, Liang, Luqun, Wang, Dan, et al. (2021b). Autophagy-related protein EI24 delays the development of pulmonary fibrosis by promoting autophagy. Life Sci. 264, 118664. doi:10.1016/j.lfs.2020.118664
Zhang, Zili, Yao, Zhen, Zhao, Shifeng, Shao, Jiangjuan, Chen, Anping, Zhang, Feng, et al. (2017). Interaction between autophagy and senescence is required for dihydroartemisinin to alleviate liver fibrosis. Cell Death Dis. 8 (6), e2886. doi:10.1038/cddis.2017.255
Zhou, Mingxia, Xu, Weimin, Wang, Jiazheng, Yan, Junkai, Shi, Yingying, Zhang, Cong, et al. (2018). Boosting MTOR-dependent autophagy via upstream TLR4-MyD88-MAPK signalling and downstream NF-?b pathway quenches intestinal inflammation and oxidative stress injury. EBioMedicine 35, 345–360. doi:10.1016/j.ebiom.2018.08.035
Zhou, Yuzheng, Zhang, Qianqian, Kong, Yangyang, Guo, Xiaohong, Zhang, Haiyan, Fan, Huiqin, et al. (2020). Insulin-like growth factor binding protein-related protein 1 activates primary hepatic stellate cells via autophagy regulated by the PI3K/akt/MTOR signaling pathway. Dig. Dis. Sci. 65 (2), 509–523. doi:10.1007/s10620-019-05798-x
Keywords: fibrosis, autophagy, intestinal fibrosis, inflammatory bowel disease, colitis, Crohn’s disease
Citation: Macias-Ceja DC, Barrachina MD and Ortiz-Masià D (2023) Autophagy in intestinal fibrosis: relevance in inflammatory bowel disease. Front. Pharmacol. 14:1170436. doi: 10.3389/fphar.2023.1170436
Received: 20 February 2023; Accepted: 06 June 2023;
Published: 15 June 2023.
Edited by:
Pei Wang, Second Military Medical University, ChinaCopyright © 2023 Macias-Ceja, Barrachina and Ortiz-Masià. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Dolores Ortiz-Masià, m.dolores.ortiz@uv.es